Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 249Sarcoma 72Thoracic 10Gastrointestinal 10Breast 8Lymphoid 7Gynecologic 6Genitourinary 6Dermatologic 5Head & Neck 4Other hematologic neoplasm 3Classical hematology 3Plasma cell 2Other solid neoplasm 2Endocrine 2NET 1Myeloid 1

Conditions

Neuroendocrine Tumors 46Neoplasms 8Carcinoid Tumor 7Neoplasm Metastasis 5Gastro-enteropancreatic neuroendocrine tumor 5Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Gastrointestinal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Serotonin Syndrome 2Sarcoma 2Pheochromocytoma 2Paraganglioma 2Neuroblastoma 2Neoplasms by Site 2Digestive System Neoplasms 2Digestive System Diseases 2Cholangiocarcinoma 2Carcinoma, Islet Cell 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Adrenal Gland Neoplasms 2von Hippel-Lindau Disease 1Vipoma 1

Interventions

dactolisib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Glioblastoma × NET × Clear all
NCT01508104 2017-08-23

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

University of Cincinnati

Phase 1 Terminated
19 enrolled
CNSEndocrineNET

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡